

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.:	10/613,736	ATTY. DOCKET NO.:	C1037.70044US00
FILING DATE:	July 3, 2003	CONFIRMATION NO.:	4723
APPLICANT:	Arthur M. Krieg et al.		
GROUP ART UNIT:	1645	EXAMINER:	Nina Archie

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		7,183,111	B2	Van Nest et al.	02-27-2007
		7,250,403	B2	Van Nest et al.	07-31-2007
		7,255,868	B2	Fearon et al.	08-14-2007
		7,279,555	B2	Peterson et al.	10-09-2007
		7,485,627	B2	Raz et al.	02-03-2009
		7,488,490	B2	Davis et al.	02-10-2009
		7,517,861	B2	Krieg et al.	04-14-2009
		7,521,063	B2	Klinman et al.	04-21-2009
		7,524,828	B2	Krieg et al.	04-28-2009
		7,534,772	B2	Weiner et al.	05-19-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,569,553	B2	Krieg	08-04-2009
		7,576,066	B2	Krieg	08-18-2009
		7,585,847	B2	Bratzler et al.	09-08-2009
		2005-0026861	A1	Kandimala et al.	02-03-2005
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009
		2009-0074851	A1	Bachmann et al.	03-19-2009
		2009-0137519	A1	Krieg et al.	05-28-2009
		2009-0142362	A1	Krieg et al.	06-04-2009
		2009-0155307	A1	Davis et al.	06-18-2009
		2009-0155212	A1	Bratzler et al.	06-18-2009
		2009-0191188	A1	Krieg et al.	07-30-2009
		2009-0202575	A1	Krieg et al.	08-13-2009

## FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		WO	01/54720	A1	Cistem Biotechnologies-GmbH	08-02-2001	

EXAMINER:

DATE CONSIDERED:

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/613,736	ATTY. DOCKET NO.: C1037.70044US00
				FILING DATE: July 3, 2003	CONFIRMATION NO.: 4723
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nina Archie
Sheet	2	of	2		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials *	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		BAINES et al., Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res. 2003 Jul;9(7):2693-700.	
		DITTMER et al., Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr Opin Microbiol. 2003 Oct;6(5):472-7. Review.	
		KLINE et al., Ch. 26: DNA Immunomodulation of asthma. In Inflammatory Mechanisms in Allergic Diseases. Ed., Zeiman et al. Marcel Dekker, Inc. 2002;551-64.	
		KRIEG et al., Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. Antisense Nucleic Acid Drug Dev. 1997 Apr;7(2):115-23.	
		UHLMANN, Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Expert Opin Biol Ther. 2001 Mar;1(2):319-28.	
		VERTHELYI et al., CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol. 2002 Feb 15;168(4):1659-63.	
		VOLLMER et al., Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antiv Ther. 2002;7:L115.	
		SENUMA et al., Therapeutic effect of CpG motifs on the development of chronic graft-versus-host disease in mice. Cytokine. 2002 Oct 7;20(1):23-9.	

[NOTE — No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287.01-163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.